I would like to ask if there is the preliminary ribosome data about TP53 R213X as well. According to the related paper, R213X and R196X are the two most frequent nonsense TP53 mutations in human tumors.
Or any reason that not choosing R213X but using R196X as the target type?
Thanks
“Around 10% of TP53 mutations are nonsense mutations (6–8) that give rise to premature termination codons (PTCs), resulting in the expression of unstable truncated p53 or complete lack of p53 expression due to nonsense-mediated mRNA decay (NMD) (11). R213X and R196X are the two most frequent nonsense TP53 mutations in human tumors, and R213X is present in about 1% of all human tumors (7, 8), corresponding to roughly 141,000 new cancer cases worldwide 2012 and estimated 236,000 cases in 2030 (12, 13). R213X is the 6th most common TP53 mutation in 12 common cancer types and the 2nd most common TP53 mutation in lung squamous cell carcinoma after R158L (6).”
Ref: https://www.frontiersin.org/articles/10.3389/fonc.2017.00323/full